Abstract
An early diagnosis of diabetes to prescribe effective and safe glucose-lowering therapy is important for organizing diabetes care. To analyze the efficacy and safety of modern glucose-lowering drugs, continuous glucose monitoring, or flash glucose monitoring, allowing a more detailed assessment of glycemic fluctuations within a specified period of time is actively introduced into real-world clinical practice. Over the past two decades, significant progress has been made in providing specialized medical care to patients with type 2 diabetes (T2D) due to the introduction of novel classes of glucose-lowering drugs into clinical practice. The mechanism of action of drugs belonging to dipeptidyl peptidase 4 (DPP-4) inhibitors is based on insulin-dependent modulation of insulin and glucagon production. Their use is characterized by a good safety profile, including an extremely low risk of hypoglycemia in T2D. The authors describe their experience with the DPP-4 inhibitor evogliptin in these patients. A strong tendency to a reduction in the total number of hypoglycemia recorded by flash monitoring, overall time below range (<3.9 mmol/l), and time below range (<3.0 mmol/l). The emergence on the Russian market of modern, available, locally produced DPP-4 inhibitors may significantly improve the safety of T2D therapy. KEYWORDS: glucose-lowering drug, continuous glucose monitoring, diabetes, diabetes care, hypoglycemia, evogliptin. FOR CITATION: Kalashnikova M.F., Teplov E.V., Likhodey N.V., Maloletkina E.S., Vavil'chenkova K.S., Glinkina I.V. Effect of dipeptidyl peptidase 4 inhibitor evogliptin on glycemic variability and time in range in patients with type 2 diabetes in real-world clinical practice compared with sulfonylureas (authors experience). Russian Medical Inquiry. 2023;7(9):598–605 (in Russ.). DOI: 10.32364/2587-6821-2023-7-9-7.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
